{"brief_title": "Telavancin for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia", "brief_summary": "The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.", "condition": ["Gram-Positive Bacterial Infections"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Telavancin", "Vancomycin, nafcillin, oxacillin, or cloxacillin"], "description": ["Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days", "Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days."], "arm_group_label": ["Telavancin", "Vancomycin, nafcillin, oxacillin, or cloxacillin"], "other_name": ["TD-6424", "VIBATIV"], "criteria": "Inclusion Criteria - Documented S. aureus bacteremia Exclusion Criteria - Patients who had received or would have received more than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization. The following agents were considered potentially effective antistaphylococcal therapy: antistaphylococcal penicillins (including nafcillin, oxacillin, or cloxacillin), cephalosporins, fluoroquinolones, glycopeptides (including vancomycin and teicoplanin) and linezolid", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Bacterial Infections", "Bacteremia", "Gram-Positive Bacterial Infections", "Oxacillin", "Vancomycin", "Telavancin", "Nafcillin", "Cloxacillin"], "id": "NCT00062647"}